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Abstract:  The title compounds 3a–j, substituted 1,5-benzothiazepines, were 
synthesized by the condensation of variously substituted chalcones 1 and 
2-aminothiophenol 2 via conventional as well as non-conventional inorganic 
solid support microwave irradiation methods. The non-conventional protocol 
offers several advantages, such as simple procedure, fast reaction rate, mild 
reaction conditions and improved yields, compared to conventional methods. 
The structures of the products 3a–j were established by elemental analysis, 
FTIR,  1H-NMR,  13C-NMR and mass spectroscopic studies. The synthesized 
compounds were also evaluated for their cytotoxicity against the human breast 
cancer cell line MDA-MB-435, with some exhibiting in vitro anti-breast cancer 
activity. 
Keywords:  1,5-benzothiazepines; 2-aminothiophenol; chalcones; anti-breast 
cancer activity. 
INTRODUCTION 
Disease poses a major threat to human beings and scientists are fighting to 
find solutions in the form of various medications. When the era of synthetic 
drugs began, it opened thousand doors for the development of various synthetic 
molecules with potential action. Chalcones are the well known intermediates for 
the synthesis of various differently sized bioactive heterocycles, such as isoxazo-
les, pyrimidines, pyrazoles, etc., which have been reported to possess various 
biological activities, such as antimicrobial,1,2 anti-inflammatory,3 antimalarial,4 
antioxidant5 and antitubercular.6 
Among these chalcone-derived heterocycles, benzothiazepines are well known 
important nitrogen and sulphur containing compounds that possess a broad spec-
trum of biological activities, such as antimicrobial,7,8 anti-convulsant,9 anti- 
-HIV,10 anti-cytotoxic,11 anticancer,12,13 DPPH free radical scavenger14 and 
inhibition of cholinesterases, ureases and α-glycosidases. Due to biological acti-
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vities, various conventional15–21 and non-conventional22–24 approaches have been 
developed for the synthesis of 1,5-benzothiazepines derivatives. 
Cancer is one of the most dangerous, fast propagating diseases of the present 
century with quite high mortality rates even in developed countries. The situation 
is even worse in undeveloped countries due to a lack of knowledge, poverty and 
the non-availability of quality drugs.25 
As part of our continuing research in the development of new bioactive he-
terocycles containing nitrogen and sulphur atoms, simple and convenient me-
thods for the transformation of chalcones into 1,5-benzothiazepines by conven-
tional and non-conventional methods are described herein. The non-conventional 
approaches were based on the observation that organic solvents in classical pro-
cedures are used in much larger quantities than the solutes they carry. Further-
more, the employment of solid supports in conjugation with microwaves26–30 
leads to high yields, remarkable reaction rate enhancements, and high catalytic 
activities with the optimum utilisation of energy. 
The anti-breast cancer activity of the synthesised compounds was also inves-
tigated. 
EXPERIMENTAL 
Materials, method and instrumentation 
All the chemicals were of AR grade and were obtained from Sigma–Aldrich and Merck. 
Melting points (m.p.) were determined in open capillaries on a Veego (VMP-PM) melting 
point apparatus and are uncorrected. The microwave-assisted reactions were realised using a 
microwave synthesizer model CATA-R (Catalyst Systems, Pune, India), operating at 700 W, 
generating 2450 MHz frequency. The purity of the compounds was routinely checked by thin 
layer chromatography (TLC) with silica gel-G (Merck). The instruments used for obtaining 
the spectroscopic data were: IR – FTIR spectrophotometer Bruker Alpha-Zn-Se; 1H-NMR 
(CDCl3, 500 MHz) and 13C-NMR (CDCl3, 125 MHz), FT–NMR spectrometer Bruker AV III. 
The elemental analysis was realised on a Carlo Erba 1108 analyzer and the obtained values 
were within the ±0.5 % of the theoretical values. Column chromatography was performed on 
silica gel (Merck, 60–120 mesh).  
General procedure for the preparing of 1,5-benzothiazepines 3a–j 
Condensation of the required chalcone (1) and 2-aminothiophenol (2) afforded the 
desired products 3a–j in good yield, as shown in Scheme 1. 
Conventional solution phase method. Compound 1 (0.010 mol) was dissolved in the 
minimum quantity of ethanol. To this, 2-aminothiophenol 2 (0.010 mol) was added and the 
resulting reaction mixture was refluxed for 3 h at 60–70 °C. Then, the mixture was acidified 
with 5–6 drops of glacial acetic acid and heating was continued for a further 4–5 h. After 
cooling, the content was poured onto crushed ice. The mixture was filtered and the solid was 
purified by recrystallization from methanol to afford compound 3a–j. 
Non-conventional solid phase method. Compound 1 (0.010 mol) was dissolved in the 
minimum quantity of DMF. To this, 2-aminothiophenol 2 (0.010 mol) and different inorganic 
solid supports (4.0 g) was added. The resulting mixture was uniformly mixed with a glass rod 
and air dried to remove the solvent. The absorbed material was irradiated inside the micro-
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wave synthesizer for a specific time at medium power level (700 W). After completion of re-
action (monitored by TLC), the reaction mixture was cooled to room temperature and the 
product was extracted with methanol (2×20 mL). Removal of the solvent and subsequent 
recrystallization with methanol resulted in analytical samples of 3a–j. For the biological eva-
luation, the experimental drugs were solubilised in DMF solvent at 400-fold the desired final 
maximum test concentration and stored frozen prior to use. 
Data of synthesized compounds are are given in Supplementary material. 
 
Scheme 1. Preparation route of novel substituted 1,5-benzothiazepines (3a–j) from variously 
substituted chalcones (1) and 2-aminothiophenol (2) via conventional and non-conventional 
methods. The conventional method involved the 7–8 h reflux whereas the non-conventional 
method involved 5–7 min under microwave irradiation. 
Biological evaluation 
Protocol for in vitro anti-cancer screening. Human tumour breast cancer cell line 
(MDA-MB-435) was used in this study. The cytotoxic activity was measured in vitro for the 
newly synthesized compounds using the sulforhodamine B stain (SRB) assay method.31,32 The 
cell lines were grown in RPMI 1640 medium containing 10 % foetal bovine serum and 2 mM 
L-glutamine. For the present screening experiment, cells were inoculated into 96-well microtiter 
plates. For the present screening experiment, cells were inoculated into 96 well microtiter 
plates in 90 µL at plating densities according to the SRB assay method. After cell inoculation, 
the microtiter plates were incubated at 37 °C, 5 % CO2, 95 % air and 100 % relative humidity 
for 24 h prior to the addition of the experimental drugs. After 24 h, one plate of the cell line 
was fixed in situ with trichloroacetic acid TCA, to represent a measurement of the cell 
population for the cell line at the time of drug addition (Tz). At the time of drug addition, an 
aliquot of frozen concentrate was thawed and diluted to 10 times the desired final maximum 
test concentration with complete medium containing test compound at a concentration of 10-3 
M. Additional three 10-fold serial dilutions were made to provide a total of four drug concen-
trations plus control. Aliquots of 10 µl of these different drug dilutions were added to the 
appropriate microtiter wells already containing 90 µl of medium, resulting in the required final 
drug concentrations. Different concentrations of the compound under test (10-7, 10-6, 10-5 and 
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10-4 M) were added to the cell monolayer. Triplicate wells were prepared for each individual 
concentration. 
After compound addition, end point measurement was performed using the “Elisa” test 
under standard conditions for taking the absorbance at particular wavelength (690 nm refe-
rence wavelength). The percent growth was calculated on a plate-by-plate basis for the test 
wells relative to the control wells. The percent growth was expressed as the ratio of the ave-
rage absorbance of the test well to the average absorbance of the control wells times 100. Using 
the six absorbance measurements (time zero (Tz), control growth (C), and test growth in the 
presence of drug at the four concentration levels (Ti)), the percentage growth was calculated at 
each of the drug concentration levels. Percentage growth inhibition was calculated as: 
100((Ti–Tz)/(C–Tz)) for concentrations for which Ti ≥ Tz, i.e., (Ti–Tz) is positive or zero, or 
100 [(Ti–Tz)/Tz] for concentrations for which Ti < Tz, i.e., (Ti–Tz) is negative. 
The dose response parameters were calculated for each test compound. The growth inhi-
bition of 50 % (GI50) was calculated from 100((Ti–Tz)/(C–Tz)) = 50, which is the drug concen-
tration resulting in a 50 % reduction in the net protein increase (as measured by SRB staining) 
compared to the control cells during the drug incubation.  
RESULTS AND DISCUSSION 
The aim of the present work was to design and synthesize some new 1,5- 
-benzothiazepine derivatives carrying biologically active thiazepine moieties that 
were expected to have anti-breast cancer activity. Substituted chalcones 1 were 
reacted with 2-aminothiophenol 2 to give 1,5-benzothiazepine derivatives 3a–j. 
The characterization data of the synthesized compounds are tabulated in Table I. 
The structures of the compounds 3a–j were determined on the basis of analytical 
and spectroscopic data (given in the Supplementary material to this paper). Thus, 
the IR spectra showed bands at around 1606 (C=N), 665 (C–S) and 862 (C–Br). 
The 1H-NMR spectra revealed the presence of a doublet at around δ 3.32 ppm, 
corresponding to the CH2 group, and a triplet at around δ 4.98 ppm, corres-
ponding to the CH group.  
In view of the immense utility of eco-friendly synthetic approaches, im-
proved syntheses of the 1,5-benzothiazepines were performed under microwave 
TABLE I. Characterization data of the synthesized compounds 
Entry  Molecular formula  M.p., °C 
Reaction time  Yield, % 
MW, min  Conventional, h MW  Conventional 
3a  C21H15Br2NO2S 80–81  5.0  6.0  78.0  64.0 
3b  C21H14Br2ClNO2S 82–83  6.0  6.5  82.0  69.0 
3c  C21H13Br2Cl2NO2S 89–90  5.5  7.0  84.0  69.0 
3d  C21H14Br2FNO2S 81–82  5.0  7.0  83.0  71.0 
3e  C21H14Br2FNO2S 87–88  6.0  5.0  86.0  71.0 
3f  C21H14Br2ClNO2S 90–91  6.0  6.0  80.0  69.0 
3g  C22H17Br2NO3S 82–83  5.0  6.5  89.0  68.0 
3h  C22H17Br2NO2S 85–86  7.0  7.5  81.0  68.0 
3i  C22H17Br2NO4S 78–79  7.0  6.0  79.0  68.0 
3j  C21H14Br3NO2S 93–94  6.0  7.5  90.0  72.0 
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irradiation. In this context, the suitability of different solid supports, i.e., acidic 
alumina, basic alumina, neutral alumina, montmorillonite K 10 and K2CO3, were 
examined. From the results given in Table II, it is clear that basic alumina was 
the most adaptable and simplest catalyst and gave good yields in the synthesis of 
the 1,5-benzothiazepines 3a–j. Finally in order to evaluate the use of microwave 
irradiation, the 1,5-benzothiazepines were also synthesised under conventional 
conditions. The yields and reaction times of the two preparation methods are 
compared in Table I. 
TABLE II. Comparative study for the synthesis of 3a–j by non-conventional MW using dif-
ferent solid supports 
Exp. No.  Medium  MW Power, W  Time, min  Temp., °C  Yield, % 
1 Alumina  acidic  700  9–10  83  57 
2 Alumina  basic  700  5–7  92  80 
3 Alumina  neutral  700  11–12  81  64 
4  Montmorillonite K 10  700  9–11  80  73 
5 Potassium  carbonate 700 12–13  72  69 
The newly synthesized compounds were evaluated for their in vitro cyto-
toxicity against a human breast cancer cell line (MDA-MB-435) with adriamycin 
(ADR) as the reference drug. The relationship between control in % growth and 
molar drug concentration was plotted to obtain the control growth of the breast 
cancer cell line (MDA-MB-435). The response parameter calculated was the 
GI50 value, which corresponds to the concentration required for a 50 % inhibition 
of cell viability (Table III). 
TABLE III. In vitro anticancer screening of the synthesised compounds against human breast 
cell line (MDA-MB-435); growth relative to the control (%), each value is the mean ± SD of 
three experiments 
Compound 
Molar drug concentration, mol dm-3 
GI50 / μM 
10-7 10-6 10-5 10-4 
3a  100.00±0.00 100.00±0.00  37.54±4.95 –41.23±16.63  28.0 
3b  99.66±0.39 97.44±2.60 68.84±6.13 –46.19±4.42  32.2 
3c  100.00±0.00 96.72±3.18  33.62±3.67 –26.90±5.27  29.5 
3d  90.95±8.00 99.99±0.01 88.24±8.34 80.39±7.35  >100 
3e  97.64±2.68 95.62±4.60 77.61±7.35 –42.53±4.99  33.9 
3f  99.88±0.20 98.75±2.01 79.60±4.71 –38.30±6.27  36.1 
3g  99.43±1.00 98.97±1.96 66.40±3.14 –33.50±6.83  34.8 
3h  98.58±2.45 96.74±3.26 84.74±7.44 –41.03±10.39  35.7 
3i  95.26±4.56 91.80±7.10 78.39±3.18 –47.86±5.12  31.9 
3j  100.00±0.00 100.00±0.00  95.98±3.56 –15.75±18.88  45.7 
ADR –22.63±8.93  –39.32±16.81  –48.07±19.26 –57.02±13.25  <0.1 
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CONCLUSIONS 
By comparing different inorganic solid supports, it was concluded that basic 
alumina was the most suitable support for the synthesis of 1,5-benzothiazepines 
via a non-conventional method, giving the products in good yields. It was ob-
served from the obtained results that most of the tested compounds showed some 
anti-breast cancer activity, as compared to the reference drug. These preliminary 
results of biologically screening of the tested compounds give an indication of 
the possible importance of the thiazepine moiety in anti-breast cancer compounds 
and give an encouraging framework in this field that may lead to the discovery of 
potent anticancer agents. 
SUPPLEMENTARY MATERIAL 
Аnalytical and spectral data of synthesized compounds are available electronically from 
http://www.shd.org.rs/JSCS/, or from the corresponding author on request. 
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ИЗВОД 
СИНТЕЗА НОВИХ ДЕРИВАТА 1,5-БЕНЗОТИАЗЕПИНА И ЊИХОВА 
IN VITRO АКТИВНОСТ ПРЕМА КАНЦЕРУ ДОЈКЕ 
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Department of Chemistry, FASC, Mody Institute of Technology and Science, Deemed University, 
Lakshmangarh, Rajasthan-332311, India 
Супституисани деривати 1,5-бензотиазепина (3а–ј) синтетисани су реакцијом конден-
зације супституисаних халкона (1) и 2-аминофенола (2) класичним и новим поступцима под 
условима микроталасног озрачивања. Нова метода има неколико предности у поређењу са 
класичном, као што су једноставнији поступак, краће реакционо време, блажи реакциони 
услови, побољшан принос. Структуре производа 3а–ј утврђене су на основу елементалне 
анализе FT-ИЦ, 1H-NMR и 13C-NMR спектроскопије и масене спектрометрије. Испитана је 
цитотоксична  активност  синтетисаних  једињења  према  ћелијској  линији  канцера  дојке 
MDA-MB-435. 
(Примљено 15. јула, ревидирано 19. децембра 2011) 
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